New FDA Guidance Aims to Accelerate Development of Non-Opioid Pain Treatments

The U.S. Food and Drug Administration (FDA) has released draft guidance intended to expedite the creation of safe and effective non-opioid pain relief alternatives, a move designed to combat the ongoing opioid crisis and reduce misuse. This initiative addresses the significant need for more options for the estimated one in five U.S. adults living with chronic pain who currently rely on opioids due to a lack of viable alternatives. The guidance, titled “Development of Non-Opioid Analgesics for Chronic Pain,” outlines key considerations for drug developers to streamline the process of bringing these critical medications to market.

The draft guidance specifically focuses on efficient drug development strategies, emphasizing approaches to clinical trial design, the selection of appropriate patient populations for studies, and the identification of meaningful outcome measures. A central tenet of the guidance is the evaluation of a drug’s ability to avoid, reduce, or eliminate the need for opioid use. It also delves into regulatory considerations for establishing indications for different categories of chronic pain, including broader classifications that may encompass multiple pain conditions or more specific indications for individual conditions. Furthermore, the document details the importance of robust safety and efficacy evaluations, the role of mechanistic understanding of both the drug and the pain conditions being treated, and the integration of statistical principles and patient-reported outcomes. The FDA also encourages the use of expedited program pathways to support development in this critical area.

This publication fulfills a mandate from Congress, specifically Section 3001(b) of the SUPPORT Act, which calls for FDA guidance to help overcome challenges in developing non-opioid pain management treatments. The FDA’s comprehensive strategy to address the opioid crisis extends beyond this guidance, encompassing required safety labeling changes for existing opioid pain medications to better reflect current evidence, increased enforcement against the importation and sale of illicit opioid products, and the facilitation of non-opioid alternative development. The agency is actively seeking public input on this draft guidance. Interested parties have a 60-day period from the date of its publication in the Federal Register to submit comments. Feedback can be provided electronically through http://www.regulations.gov or in writing to the Dockets Management Staff, ensuring to reference FDA-2025-D-0610 in the Federal Register notice.

Article by Mel Anara, based upon information from the U.S. Food and Drug Administration.

---